Arcturus Therapeutics Holdings
Stock Forecast, Prediction & Price Target
Arcturus Therapeutics Holdings (ARCT) stock Price Target by analysts
$74
Potential upside: 324.31%
Arcturus Therapeutics Holdings price prediction
What is Arcturus Therapeutics Holdings stock analysts` prediction?
Arcturus Therapeutics Holdings stock forecast: Based on 1 Wall Street analysts` predicted price targets for Arcturus Therapeutics Holdings in the last 3 months, the avarage price target is $74, with a high forecast of $NaN. The average price target represents a 324.31% change from the last price of $17.44.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Arcturus Therapeutics Holdings stock Price Target by analysts
Full breakdown of analysts given Arcturus Therapeutics Holdings price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Whitney Ijem Canaccord Genuity | 0% 0/3 | 10 months ago | $74 324.31% upside | $3.02 | StreetInsider | Previous targets (2) |
Whitney Ijem Canaccord Genuity | 0% 0/3 | about 1 year ago | $72 312.84% upside | $3.2 | TheFly | Previous targets (2) |
Ed Arce H.C. Wainwright | 0% 0/1 | about 1 year ago | $60 244.03% upside | $23.66 | StreetInsider | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 0% 0/1 | over 1 year ago | $140 702.75% upside | $39.42 | StreetInsider | Previous targets (0) |
Whitney Ijem Canaccord Genuity | 0% 0/3 | over 1 year ago | $86 393.11% upside | $26.79 | TheFly | Previous targets (2) |
Yale Jen Laidlaw | 0% 0/1 | over 1 year ago | $79 352.98% upside | $33.76 | StreetInsider | Previous targets (0) |
Gena Wang Barclays | 100% 1/1 | almost 3 years ago | $25 43.34% upside | $21.69 | StreetInsider | Previous targets (0) |
Unknown Goldman Sachs | N/A | over 3 years ago | $8 -54.12% downside | $17.4 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $14 -19.72% downside | $13.56 | Benzinga | N/A |
Madhu Kumar Goldman Sachs | 100% 1/1 | almost 4 years ago | $30 72.01% upside | $36.23 | StreetInsider | Previous targets (0) |
Arcturus Therapeutics Holdings Financial Estimates
Arcturus Therapeutics Holdings Revenue Estimates
Arcturus Therapeutics Holdings EBITDA Estimates
Arcturus Therapeutics Holdings Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $12.35M N/A | $205.75M 1564.81% | $157.74M -23.33% | Avg: $229.33M Low: $124.87M High: $380.37M avg. 45.38% | Avg: $386.60M Low: $254.16M High: $572.82M avg. 68.57% | Avg: $608.15M Low: $399.82M High: $901.10M avg. 57.30% | Avg: $1.14B Low: $754.66M High: $1.70B avg. 88.74% |
Net Income
% change YoY
| $-206.86M N/A | $9.34M 104.51% | $-29.72M -417.94% | Avg: $-60.43M Low: $-184.53M High: $97.19M avg. -103.30% | Avg: $43.46M Low: $-175.21M High: $292.37M avg. 171.92% | Avg: $143.99M Low: $79.87M High: $234.16M avg. 231.26% | Avg: $470.16M Low: $260.78M High: $764.58M avg. 226.51% |
EBITDA
% change YoY
| $-200.39M N/A | $11.66M 105.81% | $-24.16M -307.22% | Avg: $-135.34M Low: $-224.48M High: $-73.70M avg. -460.08% | Avg: $-228.16M Low: $-338.07M High: $-150.00M avg. -68.57% | Avg: $-358.91M Low: $-531.81M High: $-235.96M avg. -57.30% | Avg: $-677.45M Low: $-1.00B High: $-445.38M avg. -88.74% |
EPS
% change YoY
| -$7.86 N/A | $0.35 104.45% | -$1.12 -420.00% | Avg: -$1.99 Low: -$6.93 High: $3.65 avg. -77.57% | Avg: $1.77 Low: -$6.58 High: $10.98 avg. 188.74% | Avg: $5.41 Low: $3 High: $8.79 avg. 206.37% | Avg: $17.66 Low: $9.79 High: $28.71 avg. 226.51% |
Operating Expenses
% change YoY
| $215.21M N/A | $193.57M -10.05% | $235.95M 21.89% | Avg: $318.19M Low: $173.26M High: $527.74M avg. 34.85% | Avg: $536.38M Low: $352.64M High: $794.76M avg. 68.57% | Avg: $843.77M Low: $554.73M High: $1.25B avg. 57.30% | Avg: $1.59B Low: $1.04B High: $2.35B avg. 88.74% |
FAQ
What is Arcturus Therapeutics Holdings stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 131.59% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -184.53M, average is -60.43M and high is 97.19M.
What is Arcturus Therapeutics Holdings stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 65.00% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $124.87M, average is $229.33M and high is $380.37M.
What is Arcturus Therapeutics Holdings stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 136.01% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$6.93, average is -$1.99 and high is $3.65.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Arcturus Therapeutics Holdings stock. The most successful analyst is Whitney Ijem.